Australia's most trusted
source of pharma news
Posted 19 June 2025 AM
The corporate reputation amongst patient groups of pharmaceutical companies treating cancer remained relatively flat over the year, but specific pharmas saw their reputation rise.
PatientView's 2024 Corporate Reputation of Pharma survey canvassed 550 cancer patient groups worldwide between December 2024 and March 2025. It found the percentage of cancer patient groups stating the pharma industry's reputation was Excellent or Good fell from 63 per cent to 62 per cent year-on-year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.